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CSF analysis differentiates multiple-
system atrophy from idiopathic
late-onset cerebellar ataxia
W.F. Abdo, MD; B.P.C. van de Warrenburg, MD, PhD; M. Munneke, PhD; W.J.A. van Geel;
B.R. Bloem, MD, PhD; H.P.H. Kremer, MD, PhD; and M.M. Verbeek, PhD, MSc
Abstract—Background: Differentiating idiopathic late-onset cerebellar ataxia (ILOCA) from ataxia due to the cerebellar
subtype of multiple-system atrophy (MSA-C) can be difficult in the early stages of the disease Methods: The authors
analyzed the levels of various CSF biomarkers in 27 patients with MSA-C and 18 patients with ILOCA and obtained
cut-off points for each potential biomarker to differentiate MSA-C from ILOCA. Results: Increased levels of neurofilament
light chain (NFL) and neurofilament heavy chain (NFHp35) and decreased levels of the neurotransmitter metabolites
homovanillic acid (HVA), 5-hydroxyindoleaceticacid (5-HIAA), and 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG)
were observed in MSA-C compared with ILOCA patients. Receiver operating characteristic analysis showed high sensitiv-
ity and specificity levels for NFL, NFHp35, and MHPG analysis. At a cut-off of 24.4 ng/L for the NFL analysis, a
sensitivity of 79% and a specificity of 94% were obtained for differentiating MSA-C from ILOCA. At a cut-off point for
NFHp35 of 129.5 ng/L, sensitivity was 87% and specificity 83%. Analysis of MHPG levels (cut-off 42.5 nM) resulted in a
sensitivity of 86% with a specificity of 75%. A multivariate logistic regression model selected NFL, MHPG, and tau as
independent predictive biomarkers that separated the MSA-C and ILOCA groups. Conclusions: Increased levels of
neurofilament light chain and tau and decreased levels of 3-methoxy-4-hydroxyphenylethyleneglycol were associated with
high accuracy levels in differentiating the cerebellar subtype of multiple-system atrophy from idiopathic late-onset
cerebellar ataxia (LOCA). CSF analysis may thus serve as a useful tool in early diagnostic differentiation of LOCA.
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Multiple-system atrophy (MSA) is a sporadic pro-
gressive neurodegenerative disorder of middle to late
age, clinically characterized by a combination of par-
kinsonian, cerebellar, autonomic, and pyramidal
signs.1-4 It is pathologically characterized by degener-
ation of various neuronal structures including the
basal ganglia, brainstem, cerebellum, pyramidal
tract, intermediolateral columns, and Onuf nu-
cleus in the spinal cord.5,6 Cytoplasmic inclusions
in oligodendroglial cells consisting of aggregated
-synuclein are the neuropathologic hallmark of
MSA.7,8 In contrast, idiopathic late-onset cerebellar
ataxia (ILOCA) denotes a sporadic ataxia of un-
known cause, clinically characterized by the slowly
progressive pure cerebellar syndrome.
In most patients with the cerebellar form of MSA
(MSA-C), additional noncerebellar symptoms may
become apparent only as the disease progresses,
making MSA-C difficult to distinguish from ILOCA
in the earlier stages of the disease. However, differ-
entiating MSA-C from ILOCA is important because
of the prognostic differences between these two pa-
tient groups. Whereas ILOCA patients have a slowly
progressive disease over many years, MSA-C pa-
tients have a more progressive course with earlier
loss of mobility and a mean survival of 9 years.1,3,5,9,10
In search for diagnostic biomarkers, CSF analysis
is potentially attractive because the CSF is contigu-
ous with the extracellular fluid of brain structures.
CSF biomarkers could thus reflect the differential
pathologic changes that occur in the various neuro-
degenerative diseases. In this study, we analyzed
multiple biomarkers in CSF from patients with
MSA-C and ILOCA to investigate their ability to dif-
ferentiate between these two forms of cerebellar
degeneration.
Methods. Patients. We included all consecutive patients re-
ferred to the Department of Neurology of the Radboud University
Nijmegen Medical Centre between January 1996 and June 2003
for analysis of a sporadic late-onset cerebellar syndrome and who
underwent a lumbar puncture to exclude the possibility of an
infectious, immunologic, or paraneoplastic cause (table 1). Only
patients with MSA-C (n  27) or ILOCA (n  18) were included in
the statistical analysis, because these two disorders cause great
diagnostic uncertainty. Diagnostic evaluation included a detailed
disease history, a neurologic examination, blood pressure testing
while supine and standing, routine laboratory testing of blood and
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urine, and a brain MRI or CT. In addition, all patients underwent
extensive ancillary investigations that included metabolic screen-
ing (vitamin E, free thyroxine and thyroid-stimulating hormone,
ceruloplasmin, -fetoprotein, very long chain fatty acids, lysoso-
mal enzymes, urine organic acid, serum anti-gliadin IgG and IgM
antibodies, and anti-endomysial antibodies; not all patients un-
derwent all studies), iodobenzamide (IBZM-SPECT), neurophysio-
logic testing including anal sphincter electromyography (EMG)
and peripheral nerve conduction and EMG studies, heart rate
variability analysis, and genetic analysis of the various SCA mu-
tations (SCA1/2/3/6/7/14) or the Friedreich ataxia gene (FRDA).
In January 2005, two clinicians analyzed all the clinical patient
records retrospectively while blinded to the CSF data and estab-
lished consensus diagnosis for each case.
Disease severity was scored according to a previously described
disease stages score, which was slightly modified (stages 1.5 and
2.5 were added). The following stages were defined: stage 0  no
gait difficulties; stage 1  ataxia but walking independently;
stage 1.5  ataxia and intermittently dependent on walking aids;
stage 2  ataxia with permanent use of walking aids; stage 2.5 
ataxia and intermittently dependent on wheelchair; stage 3  ataxia
and permanently dependent on wheelchair; stage 4  death.1
The diagnosis of MSA-C was made according to the consensus
criteria proposed for probable and possible MSA.13 Patients with
predominant cerebellar features were classified as MSA-C. Pa-
tients fulfilling the clinical criteria for MSA-P (clinically domi-
nated by parkinsonism) were excluded from further analysis.
There are no widely used criteria to diagnose ILOCA. At our
center, ILOCA is diagnosed according to the following stringent
criteria: 1) age at onset 30 (as the MSA criteria state that an age
at onset of 30 years is an exclusion criterion for MSA); 2) pure
cerebellar syndrome without any noncerebellar symptoms includ-
ing extensor plantar responses and sustained orthostatic hypoten-
sion; 3) absence of severe sensory loss or severe polyneuropathy on
nerve conduction studies and EMG; 4) absence of anal sphincter
EMG abnormalities suggestive of MSA. In all 10 ILOCA patients
that had undergone anal sphincter EMG, it was found to be nor-
mal. 5) No mutation in the SCA1, 2, 3, 6, 7, and 14 genes or in the
FRDA gene. In the ILOCA group, none of the subjects who were
tested for a possible hereditary cause had an FRDA gene expan-
sion (n  12) or a mutation in one of the SCA genes (n  18). 6)
Negative family history for an ataxia syndrome; 7) absence of a
potential toxic cause that could explain the ataxia (alcoholism,
anticonvulsant drugs); 8) a slowly progressive disease course; 9)
normal (extensive) ancillary investigations including liver, kidney,
thyroid, vitamin B1, B6, B12, vitamin E, and folic acid, lactate,
cholesterol, lysosomal enzymes, organic acid, ceruloplasmin, anti-
gliadin or anti-endomysial antibodies, paraneoplastic antibodies,
and Venereal Disease Research Laboratories (VDRL) test.
Patients with an age at onset of 30 without SCA or FRDA
mutations and a negative familial history were classified as early-
onset cerebellar ataxia (EOCA). Patients were classified as auto-
somal dominant cerebellar ataxia (ADCA) if a mutation in one of
the SCA genes was found or if they had a family history suggest-
ing autosomal dominant inheritance.
The source population included 79 subjects with ataxia who
had undergone a lumbar puncture during the period 1996 through
2003. These patients carried the following diagnoses: EOCA (n 
10), ADCA (n  8), cerebellar syndromes due to various (n  16)
causes such as an infectious or autoimmune-mediated cerebellar
ataxia (n  4), paraneoplastic ataxia (n  1), alcoholic ataxia (n 
1), or patients with ataxia in whom a definite diagnosis could not
be established owing to lack of data or unclear diagnosis (n  10).
Forty-five patients were included in this study with possible
(n  1), probable (n  23), or definite (n  3) MSA-C or with
ILOCA (n  18) (table 1). Of the 27 MSA-C patients, 11 were
deceased at the time of patient record review. In all three patients
who underwent autopsy of the brain, the clinical diagnosis of
MSA-C was confirmed. The mean survival in these 11 deceased
patients was 8.0 years. Mean age at lumbar puncture, mean age
at onset, and clinical follow-up duration did not differ between
MSA-C and ILOCA patients. Mean disease duration at time of the
lumbar puncture was significantly longer in the ILOCA patients.
For determination of reference values of the brain-specific pro-
teins in CSF, we selected patients with ages between 40 and 75
who were referred to the Department of Neurology between 1998
and 2002 who underwent a lumbar puncture in a diagnostic
workup but who, after extensive examination, turned out not to
have a neurologic disease and had normal CSF cell count, hemo-
globin, bilirubin, total protein, lactate, glucose, and no oligoclonal
IgG bands. For determination of reference values of the neuro-
transmitter metabolites, we selected 26 patients with ages be-
tween 45 and 75 who underwent a lumbar puncture but did not
have any disorder expected to affect neurotransmitter
metabolism.
CSF biomarkers. Compared with ILOCA, there is a more ex-
tensive neurodegeneration in MSA-C, which could be reflected by
altered concentrations of brain-specific proteins. Furthermore, the
basal ganglia are clearly affected in MSA-C, which could result in
lower monoamine metabolites in the CSF. The following potential
biomarkers were therefore studied: neuron-specific enolase (NSE),
S-100B glial protein, myelin basic protein (MBP), glial fibrillary
acidic protein (GFAP), tau protein, neurofilament light chain
(NFL) protein, phosphorylated neurofilament heavy chain
(NFHp35) protein, the monoamines homovanillic acid (HVA)
and 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-
hydroxyphenylethyleneglycol (MHPG).
Both NSE and S-100B concentrations in CSF were analyzed
using an immunoluminometric assay (Byk Sangtec, Dietzenbach,
Germany) by using the Liaison automated analyzer (Byk
Sangtec). MBP concentrations in CSF were analyzed by using a
commercial ELISA (DSL, Webster, TX). GFAP concentrations
were analyzed by using a homemade sandwich ELISA.14,15 Tau
concentrations in CSF were analyzed by using the Innotest hTau
assay (Innogenetics, Gent, Belgium).
A previously described sandwich ELISA was used to determine
NFL levels.16 Levels of NFHp35 were determined using a modified
version of the sandwich ELISA.17 In summary, the microtiter
plates were coated with mouse anti-phosphorylated NFHp35 anti-
bodies (SMI35; Sternberger Monoclonals) and subsequently incu-
bated with bovine NFHp35 standard (ICN, Burlingame, CA) or
CSF samples, polyclonal rabbit anti-NFHp35 antibody (Affiniti
Research Products, Exeter, UK), and with polyclonal peroxidase-
labeled goat anti-rabbit antibodies (Jackson, Immunoresearch,
Westgrove, PA). Tetramethyl-benzidin (TMB) was used as a sub-
strate in the peroxidase reaction, and absorbance was read at 450
nm. Tris-buffered saline (pH 8.9) was used as washing and dilu-
tion buffer. The detection limit of the assay was calculated as the
mean plus 3 SD of the zero standard signal from 34 measure-
ments and was determined to be 17 ng/L. Mean recovery of the
assay was 91.2% (n  14). The intra-assay variation coefficient
(VC) was 8.3% at a concentration of 71 ng/L (n  12), 22.5% at a
concentration of 38 ng/L (n  12), and 2.8% at a concentration of
423 ng/L (n  12). The interassay VC was 18% at a concentration
of 35 ng/L (n  18).
HVA and 5-HIAA in CSF were measured according to previ-
ously described methods.18 As the concentrations of HVA and
5-HIAA vary in the different fractions of CSF,18 we always use the
9th to 11th millilter fraction of the obtained CSF. MHPG was
measured by using the same method with some minor modifica-
Table 1 Patient characteristics
MSA-C ILOCA p Value
No. of patients 27 18
Disease severity 1.6  0.58 1.5  0.67 NS
Age, y 61.1  7.7 61.2  10.5 NS
Age at onset, y 56.6  7.9 53.8  10.8 NS
Disease duration at time of
lumbar puncture, y
4.5  3.0 7.3  4.4 0.02
Clinical follow-up, y 2.3  1.9 2.5  2.7 NS
Disease duration at time of
last clinical visit, y
5.9  2.0 8.4  4.2 0.03
Data are presented as means  SD. The p value for differences using in-
dependent samples t test with correction for unequal variances where
applicable.
MSA-C  multiple-system atrophy dominated by cerebellar symptoms;
ILOCA  idiopathic late-onset cerebellar ataxia.
August (1 of 2) 2006 NEUROLOGY 67 475
tions.18,19 The CSF data of the neurotransmitter metabolites were
excluded from the statistical analysis in case patients or controls
were taking antiparkinsonian or antidepressive medication at the
time of the lumbar puncture because of their possible influence on
these CSF levels. This was the case in three MSA-C and one
ILOCA patients.
Statistical analysis. Differences between the MSA-C and
ILOCA patients were analyzed using the independent samples t
test with correction for unequal variances where applicable.
Spearman rank correlation test was used to test associations be-
tween quantitative variables. Receiver operator characteristic
(ROC) analysis was used to evaluate the value of the individual
biochemical variables and their optimal cut-off values with respect
to the discrimination of MSA-C from ILOCA. Multivariate logistic
regression with forward selection procedures was used to identify
variables that contributed independently to discriminate MSA-C
from ILOCA. Only variables with a p value of 0.10 were entered
in the multivariate analysis. In case of NFHp35, we also logarith-
mically transformed these data because of the non-Gaussian dis-
tribution. Graphpad Prism (San Diego, CA) and SPSS software
were used for statistical analysis.
Results. At time of the lumbar puncture, the clinical
picture of the MSA patients was as follows: In 8 patients
the clinical picture was compatible with the criteria for
probable MSA-C and in 10 with the criteria of possible
MSA-C.13 In another nine patients the clinical picture at
time of the lumbar puncture was that of an unknown cer-
ebellar ataxia not compatible with the criteria of MSA. For
the MSA patients the disease duration at time of the lum-
bar puncture was 4.5 years. These patients were followed
for a mean period of 2.3 years. The mean disease duration
at time of the last clinical picture was 5.9 years. In the
ILOCA patients the mean disease duration at time of the
lumbar puncture was 7.3 years; we followed these patients
for a mean period of 2.5 years, and the mean disease dura-
tion at time of the last clinical follow-up was 8.4 years.
CSF biomarkers in MSA-C vs ILOCA. Levels of brain-
specific proteins NFL and NFHp35 were significantly
higher in MSA-C vs ILOCA patients (figure, A and B; table
2). Tau levels were also increased in MSA-C but showed
only a trend toward significance. Furthermore, levels of all
neurotransmitter metabolites were significantly decreased
in the MSA-C group compared with the ILOCA group, with
MHPG showing the most significant difference (figure, C).
We calculated optimal cut-off values and accompanying
sensitivity and specificity values for the CSF biomarkers
with a difference (p  0.05) between MSA-C and ILOCA
(table 3). In addition, we calculated the likelihood ratio
and the area under the ROC curve. NFL analysis resulted
in the largest area under ROC curve with the best accu-
racy to differentiate between MSA-C and ILOCA (table 3).
Studies addressing the relative frequencies of the vari-
ous sporadic cerebellar ataxias are rare. In one study, 32%
of patients with a sporadic cerebellar ataxia could be clas-
sified as ILOCA.20 Another study diagnosed MSA-C in 29%
of patients presenting with a sporadic ataxia.1 So, a rough
assumption would be that in the group of sporadic cerebel-
lar ataxias, MSA-C would account for approximately 30%,
ILOCA for 30%, and other diagnoses for the remaining
40%. The proportion of MSA-C patients to ILOCA patients
in this study was 3:2. Although this is slightly different
from the 1:1 ratio extracted from the literature, we calcu-
lated positive and negative predictive values using this 3:2
ratio. The calculated positive (PPV) and negative (NPV)
predictive values for the distinction between MSA-C and
ILOCA were as follows: for NFL, the PPV was 95% with a
NPV of 76%; for NFHp35, the PPV was 85% and the NPV
was 87%; and for the MHPG analysis, the PPV was 83%
with a NPV of 80%.
We performed multivariate logistic regression to iden-
Figure. CSF levels of neurofilament light chain (A), neuro-
filament heavy chain p35 (B), and 3-methoxy-4-
hydroxyphenylethyleneglycol (C) in the cerebellar form of
multiple-system atrophy and idiopathic late-onset cerebel-
lar ataxia groups. Horizontal lines indicate mean levels.
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tify CSF variables that contributed independently to the
differentiation between MSA-C and ILOCA. All CSF pa-
rameters with a p value of 0.10 were entered in this
multivariate analysis. With use of this method, NFL,
MHPG, and tau were selected according to the following
model: X  162 – 6.4 * NFL  2.3 * MHPG – 0.5 * tau.
With use of this mathematical model, the MSA and ILOCA
groups were perfectly (100%) separated. Because two
MSA-C patients had high NFHp35 levels (figure, B), we
logarithmically transformed the NFHp35 data to obtain a
Gaussian distribution and performed an alternative multi-
variate logistic regression with substitution of NFHp35
levels by the logarithmically transformed data. This did
not alter the outcome of the multivariate analysis.
In MSA-C, all three measured neurotransmitter metab-
olites correlated well with each other, in particular 5-HIAA
with HVA (r  0.85; p  0.0001). Furthermore, NFL was
correlated with MHPG (r  0.51; p  0.03) and NFHp35
(r  0.476; p  0.02). In ILOCA, MHPG correlated with
age (r  0.68; p  0.004) and age at onset (r  0.65, p 
0.006). Tau levels correlated with age (r  0.60, p  0.009)
and age at onset (r  0.64, p  0.005), NFL (r  0.66,
p  0.004), NSE (r  0.76, p  0.0002), and MHPG (r 
0.51, p  0.05). Also, GFAP correlated with NFH (r  0.53,
p  0.03), and HVA and HIAA levels were correlated (r 
0.62; p  0.02).
Discussion. We observed clear differences in the
levels of various CSF biomarkers between MSA-C
and ILOCA, which suggests that CSF analysis could
aid in the differential diagnosis of sporadic late-onset
ataxias. First, we found that the levels of NFL and
NFHp35, but not the other brain-specific proteins,
were increased in MSA-C compared with ILOCA.
Second, the levels of the neurotransmitter metabo-
lites were decreased in MSA-C. Finally, multivariate
logistic regression analysis showed that a combina-
tion of NFL, tau, and MHPG could accurately differ-
entiate MSA-C from ILOCA.
Levels of NFL and NFHp35 were significantly in-
creased in the MSA patients and resulted in high
sensitivity and specificity levels to differentiate
MSA-C from ILOCA patients. Both animal and hu-
man studies have shown that NF proteins play a
major role in the axonal environment. NF proteins
are highly phosphorylated neuronal cytoskeleton
proteins composed of three subunits defined by their
molecular weight on sodium dodecyl sulfate gel elec-
trophoresis: 68 kd (NFL), 160 kd (NF medium
chain), and 200 kd (NFHp35). NFL is essential for
the assembly of the NF proteins and forms the back-
bone of the neurofilament structures. NF proteins
are essential for maintaining neuronal cytoskeletal
Table 2 Levels of measured CSF variables
MSA-C ILOCA Controls p Value
Neurotransmitter metabolites
HVA, nM 135  73 (22) 199  59 (14) 228  128 (31) 0.01
5-HIAA, nM 68  33 (22) 100  30 (14) 126  55 (31) 0.006
MHPG, nM 35.8  8.3 (22) 44.9  8.0 (16) 47  12 (28) 0.001
Brain-specific proteins
NFL, ng/L 42  25 (24) 11.7  7 (17) 11.3  15 (36) 0.0001
NFHp35, ng/L 234  144 (24) 115  49 (17) 83  64 (33) 0.0001
NSE, g/L 9.3  4.0 (25) 9.5  2.7 (18) 8.8  4 (68 NS
MBP, g/L 0.9  0.37 (22) 0.81  0.40 (17) 0.42  0.34 (59) NS
Tau, ng/L 309  117 (25) 237  132 (18) 171  99 (79) 0.07
GFAP, g/L 2.2  1.2 (21) 2.0  1.3 (18) 1.0  1.1 (67) NS
S-100B, g/L 2.7  0.9 (24) 2.3  0.9 (18) 2.4  0.62 (68) NS
A	42, ng/L 755  241 (25) 768  175 (18) 948  268 (78) NS
Values are means  SD (n). The p value for statistical differences between MSA-C and ILOCA using the independent samples t test with correction for
unequal variances where applicable.
MSA-C  cerebellar form of multiple-system atrophy; ILOCA  idiopathic late-onset cerebellar ataxia; HVA  homovanillic acid; 5-HIAA 
5-hydroxyindoleacetic acid; MHPG  3-methoxy-4-hydroxyphenylethyleneglycol; NFL  neurofilament light chain; NFHp35  phosphorylated neurofila-
ment heavy chain; NSE  neuron-specific enolase; MBP  myelin basic protein; GFAP  glial fibrillary acidic protein; A	42  amyloid 	-protein.
Table 3 Optimal cut-off values of the most significant CSF













NFL, ng/L 24.4 79 94 13.5 0.93 (0.86–1.0)
NFHp35, ng/L 145 87 83 6.4 0.87 (0.75–0.99)
MHPG, nM 42.5 86 75 3.5 0.81 (0.66–0.95)
HVA, nM 64 71 68 2.4 0.76 (0.60–0.91)
5-HIAA, nM 63.5 59 100 — 0.78 (0.63–0.93)
Optimal cut-off was calculated using univariate logistic regression with
ROC analysis. Sensitivity for the diagnosis of MSA is calculated by assign-
ment of MSA-C as patients and ILOCA as controls.
ROC AUC  receiver operating characteristic area under curve; MSA-C 
cerebellar form of multiple-system atrophy; ILOCA  idiopathic late-onset
cerebellar ataxia; NFL  neurofilament light chain; NFHp35  phosphor-
ylated neurofilament heavy chain; HVA  homovanillic acid; 5-HIAA 
5-hydroxyindoleacetic acid; MHPG  3-methoxy-4-
hydroxyphenylethyleneglycol.
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plasticity by influencing axonal caliber and axonal
transport.21 In a mouse model with MSA-like neuro-
degeneration and pathology, phosphorylated NFH
redistributed to the neuronal perikarya as a conse-
quence of axonal injury.22 Previous studies found ele-
vated CSF levels of NFL in neurologic diseases
associated with axonal injury such as in multiple
sclerosis.23 In a small study of patients with ALS,
higher NFL levels were present in patients with up-
per motor neuron involvement relative to those with
only lower motor neuron involvement.24 Further-
more, higher levels of NFL have been reported in
MSA-P relative to Parkinson disease.25,26 Therefore,
NF proteins could be regarded as biomarkers of de-
generation of (especially large myelinated) axons.
Axonal degeneration within, for example, the pyra-
midal tracts could thus result in higher NF protein
levels in the CSF. In this study, higher levels of NFL
and NFHp35 were observed in MSA-C, possibly re-
flecting the more widespread neuronal degeneration
that leads to secondary axonal decline in MSA-C.
Furthermore, involvement of the pyramidal tract,
which is an established feature of MSA-C pathology,
could partially have contributed to the higher levels
of NFL and NFHp35 in MSA-C.
CSF levels of tau protein tended to be increased in
the MSA-C group. Tau is a microtubule-associated
protein mainly localized in neuronal axons where it
stabilizes the microtubules that are essential for ax-
onal transport and maintains the function of neuro-
nal cytoskeleton. Similar to NF proteins, widespread
axonal degeneration in MSA-C could have resulted
in the higher CSF tau levels. The levels of other
brain-specific proteins did not differ significantly be-
tween both groups, indicating that the axonal pro-
teins (NF and tau) are a more sensitive marker for
differences in neuronal degeneration with secondary
axonal damage.
We also found that the mean levels of neurotrans-
mitter metabolites were lower in MSA-C compared
with ILOCA patients. These findings are consistent
with other publications in MSA patients and corre-
spond to the degeneration of the basal ganglia and
neurotransmitter producing nuclei in the brain-
stem.12,27 CSF MHPG was the most discriminative
neurotransmitter metabolite. MHPG is a noradren-
ergic neurotransmitter metabolite, and decreased
CSF concentrations in MSA may reflect
noradrenergic depletion caused by loss of cat-
echolaminergic neurons in the locus ceruleus and
ventrolateral medulla in MSA.28,29 Features of auto-
nomic dysfunction are observed in almost all MSA
patients and correlate with lower CSF MHPG
levels.19,29-32 The observed correlations in MSA-C be-
tween the various neurotransmitter metabolites are
in agreement with earlier publications in MSA and
Parkinson disease, suggesting that when degenera-
tion of the (monoamine-producing) basal ganglia de-
velops, this is not confined to one localized neuronal
population but simultaneously affects multiple areas
in the basal ganglia.19 These correlations were also
partially observed in ILOCA, where HVA and HIAA
were correlated. In MSA-C, levels of MHPG tended
to be decreased when levels of NFL were higher,
suggesting that in MSA ongoing axonal degeneration
(reflected by the higher NFL levels) parallels the
degeneration of noradrenaline-producing nervous
structures.
Our retrospective study has some potential short-
comings. First, the number of patients in the ILOCA
group was relatively small. However, because of our
stringent inclusion criteria for ILOCA, these patients
present a homogeneous group. Consequently, despite
the relative small numbers, we found clear differ-
ences in CSF levels. Second, logistic regression anal-
ysis was perhaps suboptimal owing to some missing
data of the CSF parameters. Third, we cannot ex-
clude some form of selection bias. It is standard pro-
cedure at our center to perform a lumbar puncture
in patients who present with a sporadic LOCA of
unknown etiology, to exclude the possibility of an
infectious, immunologic, or paraneoplastic cause.
However, occasional patients did not undergo a lum-
bar puncture, thereby introducing a selection bias.
Finally, the disease duration at the time of the lum-
bar puncture was significantly longer in the ILOCA
group. However, disease duration was not correlated
with the different CSF parameters in both groups,
meaning that this difference is not likely to explain
all observed differences. The fact that we did not
observe a correlation between CSF biomarkers and
disease duration might suggest that this assessment
could be useful early in the disease course. Further-
more, all eight patients who had CSF analysis
within 2 years of disease course had a perfect or near
perfect CSF profile compatible with their eventual
diagnosis. However, a prospective study is needed to
establish the value of early CSF biomarker analysis.
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